ArticleScience signaling2019
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Abstract read
In one paragraph
Article in Science signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.Biomarker research · 2026Review
- Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD).Cancer metastasis reviews · 2026Review
- The clinical landscape of HIF2α inhibitors in oncology.Nature reviews. Clinical oncology · 2026Review
- Rescuing the Function of Missense-Mutated Tumor SuppressorbioRxiv : the preprint server for biology · 2026Article
- HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.Cell reports. Medicine · 2026Article
- VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.Nature communications · 2026Article
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC-Induced Degradation.Angewandte Chemie (International ed. in English) · 2026Article
- Nuclear receptor corepressor 1 is a potential diagnostic and prognostic biomarker in clear cell renal cell carcinoma.Scientific reports · 2026Article
- Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer.Cancer discovery · 2025Article
- Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors.JCO precision oncology · 2025Article
- Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma.Cell death & disease · 2025Article
- HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy.Cell · 2025Article
- The Role of Perirenal Adipose Tissue in Carcinogenesis-From Molecular Mechanism to Therapeutic Perspectives.Cancers · 2025Review
- Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma.The oncologist · 2025Review
- Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.Molecular oncology · 2025Article
- Belzutifan for the treatment of renal cell carcinoma.Therapeutic advances in medical oncology · 2025Review
- Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.Nature reviews. Urology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Hilary E NicholsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3393-3013
Zeshan TariqDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Benjamin E HousdenDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Rebecca B JenningsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-5524-3235
Laura A StranskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Norbert PerrimonDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7542-472X
Sabina SignorettiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-5000-9105
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. william_kaelin@dfci.harvard.edu.ORCID 0000-0002-0574-4856
Harvard University · USBrigham and Women's Hospital · USHoward Hughes Medical Institute · USLudwig Cancer Research · BE
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MNew collections of dsRNAs and overexpression miRNA constructs to supplement RNAiR01GM067761 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI PERRIMON, NORBERT · 2003 to 2019
$15.5MThe von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8MDeveloping a Translation Pipeline for VHL Mutant MalignanciesU01CA236489 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2019 to 2026
$3.8MCross-species identification and validation of synthetic lethal relationships with VHL inactivationF32CA220849 · NCI · DANA-FARBER CANCER INST · PI NICHOLSON, HILARY ELAINE · 2017 to 2019
$179kHoward Hughes Medical InstituteNCI NIH HHS F32 CA220849NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R35 CA210068NCI NIH HHS U01 CA236489NIGMS NIH HHS R01 GM067761
Abstract
Inactivation of the
Indexed as
Synthetic Lethal MutationsAminopyridinesAnimalsBasic Helix-Loop-Helix ProteinsBenzimidazolesCarcinoma, Renal CellCell LineCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drosophila melanogasterEndothelial PAS Domain-Containing Protein 1HumansIndansKidney NeoplasmsMiceabemaciclibAminopyridinesBasic Helix-Loop-Helix ProteinsBenzimidazolesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Endothelial PAS Domain-Containing Protein 1IndanspalbociclibPiperazinesProtein Kinase InhibitorsPT2399PyridinesSulfonesVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.